Don't just stand there, do something: Strategies for the prevention of early death in acute promyelocytic leukemia: A commentary

Blood Cells, Molecules, and Diseases

Volumn 46, Issue 2, 2011, Pages 173-174

  Tallman, Martin S ^a   Manji, Gulam A ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ALBANY MEDICAL CENTER   (United States)

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; Arsenic trioxide; Leukemia therapy

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ARSENIC TRIOXIDE; DEXAMETHASONE; FIBRINOGEN; RETINOIC ACID;

BLEEDING; BLOOD ANALYSIS; BLOOD TRANSFUSION; CANCER MORTALITY; CANCER REGRESSION; CANCER RELAPSE; CARDIOMYOPATHY; CRYOPRECIPITATE; EARLY INTERVENTION; EMERGENCY TREATMENT; HUMAN; MOLECULARLY TARGETED THERAPY; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; RISK ASSESSMENT; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME;

ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; DISSEMINATED INTRAVASCULAR COAGULATION; HEMORRHAGE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; OXIDES; RECURRENCE; REMISSION INDUCTION; SURVIVAL RATE; TIME FACTORS; TREATMENT FAILURE; TRETINOIN;

EID: 79151485102     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2010.12.001     Document Type: Note

References (8)

1. Jacomo R.H., Melo R.A., Souto F.R., de Mattos E.R., de Oliveira C.T., Fagundes E.M., Bittencourt H.N., Bittencourt R.I., Bortolheiro T.C., Paton E.J., Bendlin R., Ismael S., Chauffaille Mde L., Silva D., Pagnano K.B., Ribeiro R., Rego E.M. Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines. Haematologica 2007, 92:1431-1432.
2. Park J.H., Panageas K.S., Schymura M.J., Qiao B., Jurcic J.G., Rosenblat T.L., Altman J.K., Douer D., Rowe J.M., Tallman M.S. A population-based study in acute promyelocytic leukemia (APL) suggests a higher early death rate and lower overall survival than commonly reported in clinical trials: data from the surveillance, epidemiology, and end results (SEER) program and the New York state cancer registry in the United States between 1992-2007. ASH Annu. Meet. Abstr. 2010, 872.
3. De la Serna J., Montesinos P., Vellenga E. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 2008, 111:3395-3402.
4. Tallman M.S., Lefèbvre P., Baine R.M., Shoji M., Cohen I., Green D., Kwaan H.C., Paietta E., Rickles F.R. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia. J. Thromb. Haemost. 2004, 2:1341-1350.
5. Dally N., Hoffman R., Haddad N., Sarig G., Rowe J.M., Brenner B. Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia-a single center experience in 34 patients. Thromb. Res. 2005, 116:109-114.
6. Wiley J.S., Firkin F.C. Reduction of pulmonary toxicity by prednisolone prophylaxis during all-trans retinoic acid treatment of acute promyelocytic leukemia. Australian Leukaemia Study Group, Leukemia 1995, 9:774-778.
7. Specchia G., Lo Coco F., Vignetti M., Avvisati G., Fazi P., Albano F., Di Raimondo F., Martino B., Ferrara F., Selleri C., Liso V., Mandelli F. Extramedullary involvement at relapse in acute promyelocytic leukemia patients treated or not with all-trans retinoic acid: a report by the Gruppo Italiano Malattie Ematologiche dell'Adulto. J. Clin. Oncol. 2001, 19:4023-4028.
8. Montesinos P., González J.D., González J., Rayón C., de Lisa E., Amigo M.L., Ossenkoppele G.J., Peñarrubia M.J., Pérez-Encinas M., Bergua J., Debén G., Sayas M.J., de la Serna J., Ribera J.M., Bueno J., Milone G., Rivas C., Brunet S., Löwenberg B., Sanz M. Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic acid and anthracycline-based chemotherapy. J. Clin. Oncol. 2010, 28:3872-3879.